[HTML][HTML] The immunology of COVID-19: is immune modulation an option for treatment?
J Zhong, J Tang, C Ye, L Dong - The Lancet Rheumatology, 2020 - thelancet.com
In December, 2019, an outbreak of COVID-19 emerged in Wuhan, China and quickly spread
globally. As of May 7, 2020, there were 3 672 238 confirmed infections and 254 045 deaths …
globally. As of May 7, 2020, there were 3 672 238 confirmed infections and 254 045 deaths …
Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19)
pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily …
pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily …
[HTML][HTML] Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo …
L Shi, H Huang, X Lu, X Yan, X Jiang, R Xu… - Signal transduction and …, 2021 - nature.com
Abstract Treatment of severe Coronavirus Disease 2019 (COVID-19) is challenging. We
performed a phase 2 trial to assess the efficacy and safety of human umbilical cord …
performed a phase 2 trial to assess the efficacy and safety of human umbilical cord …
[HTML][HTML] Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report
B Liang, J Chen, T Li, H Wu, W Yang, Y Li, J Li, C Yu… - Medicine, 2020 - journals.lww.com
Interventions: After regular treatment for 12 days, the inflammation symptom of the patient
was still very severe and the potential side effects of corticosteroid were observed. Then …
was still very severe and the potential side effects of corticosteroid were observed. Then …
[HTML][HTML] Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management
COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress
syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even …
syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even …
[HTML][HTML] AdMSC-derived exosomes alleviate acute lung injury via transferring mitochondrial component to improve homeostasis of alveolar macrophages
L Xia, C Zhang, N Lv, Z Liang, T Ma, H Cheng, Y Xia… - Theranostics, 2022 - ncbi.nlm.nih.gov
Rationale: Aberrant activation of macrophages with mitochondria dismiss was proved to be
associated with pathogenesis of ALI (acute lung injury). Exosomes from adipose-derived …
associated with pathogenesis of ALI (acute lung injury). Exosomes from adipose-derived …
Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer
TJ Morrison, MV Jackson, EK Cunningham… - American journal of …, 2017 - atsjournals.org
Rationale: Acute respiratory distress syndrome (ARDS) remains a major cause of respiratory
failure in critically ill patients. Mesenchymal stromal cells (MSCs) are a promising candidate …
failure in critically ill patients. Mesenchymal stromal cells (MSCs) are a promising candidate …
[HTML][HTML] Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model
M Khatri, LA Richardson, T Meulia - Stem cell research & therapy, 2018 - Springer
Background Mesenchymal stem (stromal) cells (MSCs) mediate their immunoregulatory and
tissue repair functions by secreting paracrine factors, including extracellular vesicles (EVs) …
tissue repair functions by secreting paracrine factors, including extracellular vesicles (EVs) …
[HTML][HTML] Human mesenchymal stem cells (MSCs) for treatment towards immune-and inflammation-mediated diseases: review of current clinical trials
LT Wang, CH Ting, ML Yen, KJ Liu, HK Sytwu… - Journal of biomedical …, 2016 - Springer
Human mesenchymal stem cells (MSCs) are multilineage somatic progenitor/stem cells that
have been shown to possess immunomodulatory properties in recent years. Initially met with …
have been shown to possess immunomodulatory properties in recent years. Initially met with …
[HTML][HTML] MSC based therapies—new perspectives for the injured lung
J Behnke, S Kremer, T Shahzad, CM Chao… - Journal of clinical …, 2020 - mdpi.com
Chronic lung diseases pose a tremendous global burden. At least one in four people suffer
from severe pulmonary sequelae over the course of a lifetime. Despite substantial …
from severe pulmonary sequelae over the course of a lifetime. Despite substantial …